Main Management ETF Advisors LLC Cuts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Main Management ETF Advisors LLC cut its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 8.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,464 shares of the company’s stock after selling 3,008 shares during the quarter. Main Management ETF Advisors LLC’s holdings in Hims & Hers Health were worth $809,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the period. Blume Capital Management Inc. boosted its position in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $64.02 on Wednesday. The business’s 50-day simple moving average is $33.85 and its two-hundred day simple moving average is $32.96. The company has a market cap of $14.33 billion, a PE ratio of 145.50 and a beta of 1.84. Hims & Hers Health, Inc. has a fifty-two week low of $13.12 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the prior year, the firm earned $0.05 earnings per share. Hims & Hers Health’s revenue for the quarter was up 110.7% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $29.26, for a total transaction of $338,860.06. Following the completion of the transaction, the chief financial officer now directly owns 124,104 shares of the company’s stock, valued at $3,631,283.04. The trade was a 8.54% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 563,973 shares of company stock valued at $21,951,757. Company insiders own 13.71% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Piper Sandler reaffirmed a “neutral” rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. TD Cowen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating and lowered their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Morgan Stanley reduced their price target on Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.